Land: Singapúr
Tungumál: enska
Heimild: HSA (Health Sciences Authority)
INFLUENZA VIRUS (NH) A/California/7/2009 (H1N1)pdm09-Derived Strain
SANOFI-AVENTIS SINGAPORE PTE. LTD.
J07BB02
9 mcg HA/0.1ml
INJECTION, SUSPENSION
INTRADERMAL
Prescription Only
SANOFI WINTHROP INDUSTRIE
2011-11-03
INTANZA 9 MICROGRAMS, SUSPENSION FOR INJECTION 1. NAME OF THE MEDICINAL PRODUCT Intanza 9 microgram/strain suspension for injection Influenza vaccine (split virion, inactivated) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus (inactivated, split) of the following strains*: A/California/7/2009 (H1N1)pdm09-derived strain used (NYMC X-179A)…………9 micrograms HA** A/Texas/50/2012 (H3N2)-derived strain used (NYMC X-223A). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . …………………………9 micrograms HA** B/Massachusetts/2/2012. . .. .……………………………………………..9 micrograms HA** Per 0.1 ml dose * Propagated in fertilised hens’ eggs from healthy chicken flocks ** Haemagglutinin This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2014/2015 season. For the full list of excipients, see section 6.1. Intanza ma y contain residues of eggs such as ovalbumin and residues of neomycin, formaldehyde and octoxinol-9, which are used during the manufacturing process (see section 4.3). 3. PHARMACEUTICAL FORM Suspension for injection. Colourless and opalescent suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza in adults up to 59 years of age, especially in those who run an increased risk of associated complications. The use of Intanza should be based on official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION 1 Posology Adults up to 59 years of age: 0.1 ml. _Paediatric populat Lestu allt skjalið